How to Get a GLP-1 Prescription in 2026: The Patient Buyer Funnel

Most patients searching “how to get semaglutide” don't realize there are at least four legitimate paths to a GLP-1 prescription in the US in 2026 — each with different costs, different paperwork, and different waiting times. This is the buyer funnel: insurance, brand-name direct-pay, compounded telehealth, and the new oral Foundayo route. Plus the red flags that mean you're looking at an illegitimate seller, not a real pharmacy.

Step 1: Are you eligible at all?

The FDA-approved indication for chronic weight management with Wegovy^[1] and Zepbound^[2] is identical:

• Adults with BMI ≥ 30 (any class of obesity), OR
• Adults with BMI ≥ 27 AND at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, or established cardiovascular disease.

If you're below BMI 27, the FDA-approved labeling doesn't cover you, and most insurance and brand-name direct-pay programs will not cover you either. You can check your eligibility in two minutes with our BMI calculator. Off-label prescribing exists but is rare for weight management at lower BMIs.

Path 1 — Through insurance

The cheapest path if it works, and the most paperwork-heavy.

1a. Check if your plan covers GLP-1s for weight management

Most commercial insurance plans cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro). Far fewer cover them for weight management (Wegovy, Zepbound). Coverage varies by employer, not just by carrier — Aetna at one employer might cover Wegovy with prior authorization while Aetna at a different employer carves it out completely. The fastest way to find out is:

• Use our insurance employer checker to see what 30 large US employers cover.
• Call the member-services number on the back of your insurance card and ask specifically: “Is Wegovy on my formulary for weight management? What about Zepbound? Is prior authorization required? What is my copay at each tier?”
• Check our insurance coverage 2026 article for the Medicare, Medicaid, and commercial landscape.

1b. Get a prescriber to write the prescription

You need either a PCP, an obesity-medicine physician, or an endocrinologist who is willing to prescribe a GLP-1 for weight management. Bring documented BMI from a clinical visit (not self-reported) and any comorbidity diagnoses (lab values for diabetes or pre-diabetes, blood pressure readings for hypertension, sleep study results for OSA).

1c. Survive prior authorization

Almost all insurance approvals for weight-management GLP-1s require a prior authorization (PA) form. The PA typically asks for:

• Documented BMI ≥ 30 (or ≥ 27 with a specific comorbidity)
• Documentation of a previous lifestyle program (diet, exercise, often a specific commercial program like Weight Watchers, Noom, or a hospital-based program)
• Often a previous medication trial (Qsymia, Contrave, phentermine — “step therapy”)
• Sometimes a sleep study or other comorbidity workup

The PA process typically takes 3-14 days. Denials are common; most can be appealed successfully if your prescriber provides additional clinical documentation.

Realistic out-of-pocket on insurance: if your plan covers the drug at the brand tier, copays range from $25-$100/month for most commercial plans. If you have a high-deductible plan, you may pay full retail until you meet the deductible.

Path 2 — Brand-name direct-pay (no insurance, no PA)

Both Novo Nordisk and Eli Lilly run patient-direct cash-pay programs that bypass insurance and PBM step therapy entirely. This is the path most patients take when their insurance doesn't cover weight-management GLP-1s.

2a. Wegovy NovoCare^[3]

• $499/month for the standard pen (any dose strength). Available to anyone in the US with a valid prescription, no insurance required.
• $199/month for the “all dose strengths” subscription if you're paying out of pocket and not using insurance. Includes free shipping.
• You still need a prescription from a US-licensed prescriber. NovoCare does not include the prescriber visit.

2b. Zepbound LillyDirect^[4]

Lilly cut LillyDirect Zepbound prices on December 1, 2025. Current self-pay tiers:

• $299/month for the 2.5 mg starter dose
• $399/month for the 5 mg dose
• $449/month for the 7.5 mg and higher doses
• Available to any US patient with a valid prescription. LillyDirect ships to all 50 states.

2c. Foundayo (oral) — the new option^[5]

Foundayo (orforglipron) is the first non-peptide oral GLP-1, FDA-approved April 1, 2026. Lilly is positioning it aggressively against the injectables on price:

• $25/month with the Lilly Savings Card for commercially insured patients (not Medicare or Medicaid)
• $149/month list price for cash-pay patients without insurance
• Pill, taken daily — no injection, no refrigeration
• The FDA-approved labeled maintenance dose (17.2 mg) produced 11.1% mean weight loss in adults without type 2 diabetes at 72 weeks per the Foundayo prescribing information (less than Wegovy and Zepbound, but real)

Foundayo is the cheapest legal path to a brand-name GLP-1 in 2026 if you have commercial insurance. See our Foundayo approval deep-dive for the full clinical context.

Path 3 — Compounded telehealth

Compounded semaglutide and tirzepatide are made by 503A compounding pharmacies, not by Novo Nordisk or Lilly. They are typically prescribed and dispensed through telehealth platforms that bundle the prescriber visit, the medication, and the shipping into a single subscription.

3a. Pricing range

• $150-$250/month for compounded semaglutide at most reputable telehealth platforms (Hims, Henry Meds, Mochi Health, EmpowerRX, etc.)
• $250-$400/month for compounded tirzepatide
• See our live compounded pricing index for the median, p10, and p90 across the entire telehealth market.

3b. The shortage status caveat

Compounded GLP-1s exist legally because of FDA drug shortage rules under section 503A of the Federal Food, Drug, and Cosmetic Act. Tirzepatide came off the FDA shortage list in October 2024^[7], and semaglutide came off in early 2025. Compounding remains legal under the “clinical difference” provision (different dose, different concentration, different delivery), but FDA has issued multiple warning letters to compounders and marketers — see our FDA warning letters tracker.

3c. How to vet a compounded telehealth provider

• PCAB accreditation on the dispensing pharmacy^[8] — this is the gold standard for compounding quality.
• Pharmacy state license — every legitimate compounder is registered with at least one US state board of pharmacy. The license number should be visible on the provider's site or available on request.
• Real prescriber visit — a video visit or a structured intake reviewed by a physician, NP, or PA licensed in your state. If the provider just asks you to tick boxes on a form and ships the drug, that's a red flag.
• See our PCAB accreditation investigation for our full vetting framework.

Path 4 — “Research peptides” and grey-market sellers (DON'T)

There is a large grey market of websites selling “research peptide” semaglutide and tirzepatide — vials labeled “not for human consumption” that are obviously marketed to humans. These are not legal pharmacies, are not regulated by the FDA, and have been the source of multiple contamination, dose-error, and counterfeit incidents.

The FDA has issued specific consumer warnings about unapproved GLP-1 products^[6]. Red flags:

• No prescription required, no prescriber visit
• No state pharmacy license listed
• Vials labeled “for research use only” or “not for human consumption”
• Prices significantly below the legitimate compounded range (e.g., <$50/month for tirzepatide)
• Payment in cryptocurrency only
• Shipping from outside the US
• No US business address or customer service phone number

The risks include incorrect dosing, contamination, counterfeit material with no active drug, and the lack of any recourse if something goes wrong. Don't do it.

Decision tree — which path probably fits you

• You have commercial insurance and your plan covers weight-management GLP-1s → Path 1 (insurance). $25-$100/mo copay if approved.
• You have commercial insurance but your plan does NOT cover weight management → Path 2c (Foundayo $25/mo with savings card) is the cheapest. Path 2a/2b ($199-$499/mo) if you specifically want an injectable.
• You have no insurance at all → Path 3 (compounded, $150-$400/mo) is usually the cheapest. Path 2 (NovoCare $199 or LillyDirect $299) is more expensive but is brand-name and avoids any compounding uncertainty.
• You have Medicare → coverage for weight management is limited; see our insurance coverage article for the current Medicare situation.
• You have Medicaid → coverage varies enormously by state; some states cover with PA, many do not.

What this article is NOT

This is a buyer's guide, not a recommendation to buy. Whether a GLP-1 is right for you depends on your medical history, your weight loss goals, your budget, and your tolerance for the GI side effects covered in our side effect Q&A and nausea management guide. Discuss the decision with a prescribing clinician who knows your medical history before you start.

Bottom line

• Four legitimate paths in 2026: insurance, brand-name direct-pay (NovoCare/LillyDirect/Foundayo savings card), compounded telehealth, and Medicaid/Medicare.
• Cheapest if commercially insured: Foundayo $25/mo with savings card.
• Cheapest if uninsured: compounded telehealth $150-$400/mo OR Wegovy NovoCare at $199/mo for the all-dose subscription.
• You need a real prescriber, real BMI documentation, and a willingness to push back on insurance denials.
• Don't buy “research peptides” from unlicensed grey-market sellers — they are not legal pharmacies and have caused real patient harm.

Related research and tools

• GLP-1 savings calculator 2026 — compare 10 different access paths over 1, 5, and 10 years
• GLP-1 BMI calculator — check FDA eligibility in 30 seconds
• Insurance employer checker — coverage at 30 large US employers
• GLP-1 compounded pricing index 2026 — live median, p10, and p90 across the telehealth market
• Insurance coverage 2026: Medicare, Medicaid, commercial
• Wegovy pen vs compounded vial — practical differences

Important disclaimer. This article is educational and does not constitute medical advice or a recommendation to use any particular drug, pharmacy, or program. Pricing is current as of April 2026 and is updated as the manufacturer programs change. Discuss any decision to start a GLP-1 with a prescribing clinician who knows your full medical history.